NCT04851119 2026-02-24Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid TumorsChildren's Oncology GroupPhase 1/2 Recruiting147 enrolled
NCT05296564 2025-10-02Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic CancersHadassah Medical OrganizationPhase 1/2 Recruiting3 enrolled